GeneReach Biotechnology (4171) — Working Capital to Net Assets Ratio
GeneReach Biotechnology (4171) has a Working Capital to Net Assets ratio of 47.4% as of December 2025. Working capital of NT$283.03 Million (current assets of NT$484.16 Million minus current liabilities of NT$201.13 Million) is measured against net assets of NT$596.72 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See 4171 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
GeneReach Biotechnology Working Capital to Net Assets (2017–2025)
This chart shows how GeneReach Biotechnology's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of December 2025, the ratio stands at 47.4%, reflecting working capital of NT$283.03 Million against net assets of NT$596.72 Million TWD. See 4171 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for GeneReach Biotechnology (2017–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for GeneReach Biotechnology from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see GeneReach Biotechnology market capitalisation.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 47.4% | NT$283.03 Million | NT$596.72 Million | NT$484.16 Million | NT$201.13 Million | ▼ -1.5 pp |
| 2024 | 49.0% | NT$355.14 Million | NT$725.49 Million | NT$594.67 Million | NT$239.53 Million | ▼ -0.5 pp |
| 2023 | 49.4% | NT$426.24 Million | NT$862.44 Million | NT$632.14 Million | NT$205.90 Million | ▼ -12.7 pp |
| 2022 | 62.1% | NT$684.99 Million | NT$1.10 Billion | NT$1.07 Billion | NT$385.09 Million | ▼ -20.8 pp |
| 2021 | 82.9% | NT$902.32 Million | NT$1.09 Billion | NT$1.18 Billion | NT$278.21 Million | ▲ +18.4 pp |
| 2020 | 64.5% | NT$553.50 Million | NT$857.76 Million | NT$798.64 Million | NT$245.14 Million | ▲ +11.9 pp |
| 2019 | 52.6% | NT$312.23 Million | NT$593.05 Million | NT$399.91 Million | NT$87.68 Million | ▲ +33.3 pp |
| 2018 | 19.4% | NT$60.31 Million | NT$311.15 Million | NT$432.70 Million | NT$372.39 Million | ▲ +42.0 pp |
| 2017 | -22.6% | NT$-56.73 Million | NT$250.63 Million | NT$282.67 Million | NT$339.40 Million | — |